Liver metastases grow at widely different rates depending on the type of cancer they originated from, but a commonly cited average is a tumor volume doubling time of roughly 86 to 155 days. That means a single lesion can double in size in as little as three months or take more than five months. Some types, like neuroendocrine tumors, grow so slowly they can remain stable for years, while others can cause life-threatening liver enlargement in weeks.
Doubling Times by Cancer Type
The most detailed growth data comes from colorectal cancer, the most common source of liver metastases. A study tracking colorectal liver metastases found two distinct patterns. Metastases that were already visible at the time of the original surgery doubled in volume every 155 days on average (about five months). Hidden metastases, ones too small to detect during surgery but discovered later, doubled every 86 days (about three months). The faster growth of these smaller, initially undetectable tumors likely reflects that they were in an earlier, more aggressive growth phase.
That same research estimated how long the metastases had been growing before they were found. The visible ones had been present for roughly 3.7 years on average, while the hidden ones had been growing for about 2.3 years. This means liver metastases often exist long before they show up on imaging, growing silently from microscopic clusters of cells.
Breast cancer liver metastases follow a different timeline. Triple-negative breast cancer, the most aggressive subtype, tends to spread to the liver within about 15 months of diagnosis. Hormone receptor-positive subtypes take longer, typically 30 to 34 months. Once breast cancer reaches the liver, median survival with treatment is 2 to 3 years.
Neuroendocrine tumors sit at the other end of the spectrum. These cancers often have an indolent course even after spreading to the liver. In clinical trials, patients with untreated neuroendocrine liver metastases had a median time to progression of 6 months, but with treatment that extended to over 14 months. Many patients live years with stable or slowly growing neuroendocrine liver metastases.
Why the Liver Is Vulnerable to Fast-Growing Metastases
The liver receives an enormous blood supply from two sources: the portal vein (carrying nutrient-rich blood from the digestive tract) provides 70 to 80% of blood flow, while the hepatic artery delivers the remaining 20 to 30%, rich in oxygen. This dual supply makes the liver a hospitable landing site for cancer cells circulating in the bloodstream.
Once metastases establish themselves, they hijack mainly the arterial blood supply. High-pressure arterial blood flows into the small vessels surrounding the tumor, actually blocking the lower-pressure portal vein blood from entering. This arterial dependence is what makes certain treatments possible: blocking the arterial supply to a tumor through embolization can cut off its primary fuel source, at least temporarily. The portal vein can partially compensate, so completely starving a liver tumor of blood through a single approach is difficult.
Growth Isn’t Always Steady
Liver metastases don’t grow at a constant rate. They follow a pattern called Gompertzian growth, where smaller tumors grow faster and larger ones gradually slow down. A tiny cluster of cancer cells may double rapidly every few weeks, but as the tumor grows and outpaces its blood supply, the doubling time stretches. This is why the hidden, smaller colorectal metastases in the study above doubled nearly twice as fast as the larger, visible ones.
This growth pattern has practical implications. A scan showing a small new lesion doesn’t necessarily mean the cancer just appeared. It may have been growing for months or years and only recently reached the 1-centimeter threshold where imaging reliably picks it up. Conversely, a period of apparent stability on scans doesn’t always mean the cancer has stopped. It may simply be in the slower phase of its growth curve.
How Growth Is Tracked on Imaging
Doctors use a standardized system called RECIST 1.1 to determine whether liver metastases are growing, stable, or shrinking. Progressive disease is defined as a 20% or greater increase in the combined diameter of target lesions, with at least a 5-millimeter absolute increase. The appearance of any new lesion also counts as progression, regardless of size changes in existing tumors.
After surgery or ablation to treat liver metastases, imaging with CT or MRI is typically recommended every 3 to 6 months for the first two years. After that, the interval stretches to every 6 to 12 months. This schedule is designed to catch regrowth early, since recurrence risk is highest in the first two years. Patients who have had localized treatment like ablation are considered particularly high risk and are usually scanned on the shorter end of that range.
When Growth Becomes Rapid
In rare but serious cases, liver metastases can expand so quickly that they stretch the liver’s outer capsule, a fibrous covering packed with nerve endings. This stretching causes distinctive symptoms: worsening right upper abdominal pain, pain with coughing or sneezing, abdominal distension, loss of appetite, and weight loss. Case reports describe patients whose livers enlarged so rapidly that they progressed from initial symptoms to liver failure in under two weeks.
More commonly, growing liver metastases cause a gradual onset of symptoms. Early on, most people feel nothing at all. As tumors enlarge or multiply, fatigue and a vague sense of fullness after eating are often the first signs. Jaundice, a yellowing of the skin and eyes, typically signals that tumors are obstructing bile ducts or that the liver is losing enough functional tissue to impair its ability to process bilirubin.
The overall trajectory varies so much between cancer types and individual patients that growth rate alone doesn’t predict outcome. A single doubling-time number from a scan gives your oncologist useful information for treatment planning, but it’s one data point among many, including how much healthy liver remains, how the cancer responds to systemic therapy, and whether the metastases are confined to the liver or have spread elsewhere.